150 related articles for article (PubMed ID: 33434277)
1. Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial.
Stouten V; Westhovens R; De Cock D; Van der Elst K; Pazmino S; Bertrand D; Joly J; Verschueren P
Rheumatology (Oxford); 2021 Aug; 60(8):3699-3708. PubMed ID: 33434277
[TBL] [Abstract][Full Text] [Related]
2. Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis.
Batko B; Urbański K; Świerkot J; Wiland P; Raciborski F; Jędrzejewski M; Koziej M; Cześnikiewicz-Guzik M; Guzik TJ; Stajszczyk M
Clin Rheumatol; 2019 Sep; 38(9):2473-2481. PubMed ID: 31076943
[TBL] [Abstract][Full Text] [Related]
3. Co-morbidities in Finnish patients with rheumatoid arthritis: 15-year follow-up.
Tiippana-Kinnunen T; Kautiainen H; Paimela L; Leirisalo-Repo M
Scand J Rheumatol; 2013; 42(6):451-6. PubMed ID: 23826623
[TBL] [Abstract][Full Text] [Related]
4. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Bertrand D; Verschueren P
Ann Rheum Dis; 2021 Aug; 80(8):965-973. PubMed ID: 33811036
[TBL] [Abstract][Full Text] [Related]
5. Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis.
Putrik P; Ramiro S; Lie E; Michaud K; Kvamme MK; Keszei AP; Kvien TK; Uhlig T; Boonen A
Rheumatology (Oxford); 2018 Mar; 57(3):548-554. PubMed ID: 29272517
[TBL] [Abstract][Full Text] [Related]
6. Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
Doumen M; De Cock D; Pazmino S; Bertrand D; Joly J; Westhovens R; Verschueren P
Arthritis Res Ther; 2021 Oct; 23(1):269. PubMed ID: 34706771
[TBL] [Abstract][Full Text] [Related]
7. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
Pazmino S; Boonen A; Stouten V; De Cock D; Joly J; Van der Elst K; Westhovens R; Verschueren P
Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
[TBL] [Abstract][Full Text] [Related]
10. Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis.
Yu C; Li M; Duan X; Fang Y; Li Q; Wu R; Liu S; Wang Y; Wu Z; Shi X; Jiang Z; Wang Y; Hsieh ED; Jin S; Jiang N; Wang Q; Zhao Y; Tian X; Zeng X;
Clin Exp Rheumatol; 2018; 36(5):836-840. PubMed ID: 29600939
[TBL] [Abstract][Full Text] [Related]
11. Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network.
Nikiphorou E; Norton SJ; Carpenter L; Walsh DA; Creamer P; Dixey J; Young A; Kiely PDW;
Rheumatology (Oxford); 2020 Jun; 59(6):1272-1280. PubMed ID: 31580448
[TBL] [Abstract][Full Text] [Related]
12. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Verschueren P;
Rheumatology (Oxford); 2019 Dec; 58(12):2284-2294. PubMed ID: 31236568
[TBL] [Abstract][Full Text] [Related]
14. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
[TBL] [Abstract][Full Text] [Related]
15. Co-morbidity in patients with early rheumatoid arthritis - inflammation matters.
Innala L; Sjöberg C; Möller B; Ljung L; Smedby T; Södergren A; Magnusson S; Rantapää-Dahlqvist S; Wållberg-Jonsson S
Arthritis Res Ther; 2016 Jan; 18():33. PubMed ID: 26818851
[TBL] [Abstract][Full Text] [Related]
16. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
18. Co-morbidities in established rheumatoid arthritis.
Gullick NJ; Scott DL
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):469-83. PubMed ID: 22137918
[TBL] [Abstract][Full Text] [Related]
19. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
[TBL] [Abstract][Full Text] [Related]
20. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
